Literature DB >> 3497039

Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses.

R J Francis, J G Allen, D Looi, J S Dixon, H A Bird, V Wright.   

Abstract

Single oral dose pharmacokinetics of tenoxicam in the dose range intended for therapeutic application of the drug have been defined in healthy human subjects. Twelve male volunteers were given, in random fashion, oral administration of 10, 20 or 40 mg of tenoxicam. Plasma drug levels were determined by a standard HPLC method with U.V. detection. Model-independent analysis showed the clearance, elimination half-life and apparent volume of distribution to be independent of dose with mean values of 0.096 L/h, 76 h and 9.2 L respectively. Interindividual variation was six-fold and individual variation less than two-fold. Similar values for kinetic parameters were obtained by model-dependent methods. The pharmacokinetics of oral tenoxicam were linear in the 10-40 mg dose range and the single dose data predict five-fold accumulation for once daily administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497039     DOI: 10.1007/BF03189862

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  6 in total

1.  Rapid method for the determination of either piroxicam or tenoxicam in plasma using high-performance liquid chromatography.

Authors:  J S Dixon; J R Lowe; D B Galloway
Journal:  J Chromatogr       Date:  1984-10-12

2.  ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.

Authors:  R J Francis
Journal:  Comput Programs Biomed       Date:  1984 Feb-Apr

3.  A double-blind, parallel study of tenoxicam and piroxicam in patients with osteoarthrosis.

Authors:  H A Bird; J Hill; J S Dixon; D Looi; V Wright
Journal:  Curr Med Res Opin       Date:  1985       Impact factor: 2.580

4.  Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly.

Authors:  H A Bird; R J Francis; P Le Gallez; J Hill; J S Dixon; J G Allen; V Wright
Journal:  Eur J Rheumatol Inflamm       Date:  1985

5.  Pharmacokinetics of tenoxicam in healthy human volunteers.

Authors:  R C Heintz; T W Guentert; J F Enrico; U C Dubach; R Brandt; F S Jeunet
Journal:  Eur J Rheumatol Inflamm       Date:  1984

6.  A double-blind comparison of tenoxicam (Tilcotil, Mobiflex) at two doses against ibuprofen in rheumatoid arthritis.

Authors:  H A Bird; J Hill; J R Lowe; V Wright
Journal:  Eur J Rheumatol Inflamm       Date:  1984
  6 in total
  6 in total

1.  The effect of concurrent aspirin upon plasma concentrations of tenoxicam.

Authors:  R O Day; P D Paull; S Lam; B R Swanson; K M Williams; D N Wade
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

2.  Intraocular and plasma kinetics of tenoxicam in rabbits.

Authors:  M Del Puppo; M G Kienle; R Ratiglia; D Galimberti; G Acerbi; L Boerci; L Marabini; E Chiesara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

Review 3.  Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 4.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

6.  Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam.

Authors:  C Benveniste; R Striberni; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.